Estrogen Receptor Modulators
"Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure.
| Descriptor ID |
D020847
|
| MeSH Number(s) |
D06.347.360 D27.505.696.399.450.360
|
| Concept/Terms |
Estrogen Receptor Modulators- Estrogen Receptor Modulators
- Modulators, Estrogen Receptor
- Receptor Modulators, Estrogen
- Antiestrogens
- Antiestrogen
- Estrogen Receptor Modulator
- Modulator, Estrogen Receptor
- Receptor Modulator, Estrogen
|
Below are MeSH descriptors whose meaning is more general than "Estrogen Receptor Modulators".
Below are MeSH descriptors whose meaning is more specific than "Estrogen Receptor Modulators".
This graph shows the total number of publications written about "Estrogen Receptor Modulators" by people in this website by year, and whether "Estrogen Receptor Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Estrogen Receptor Modulators" by people in Profiles.
-
Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther. 2011 Nov 15; 12(10):924-38.
-
Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol. 2011 Jun 20; 29(18):2448-58.
-
Christopher TA, Lopez BL, Stillwagon JC, Gao F, Gao E, Ma XL, Ohlstein EH, Yue TL. Idoxifene causes endothelium-dependent, nitric oxide-mediated vasorelaxation in male rats. Eur J Pharmacol. 2002 Jun 20; 446(1-3):139-43.
-
Brady H, Desai S, Gayo-Fung LM, Khammungkhune S, McKie JA, O'Leary E, Pascasio L, Sutherland MK, Anderson DW, Bhagwat SS, Stein B. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res. 2002 Mar 01; 62(5):1439-42.